Slide 1: Q2 & Half-Year Report
Q2 & HALF-YEAR REPORT August 28, 2024
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: News flow during/after period
News flow during/after period… The CAN10 clinical trial passed important milestones: • Eight SAD groups completed • Independent safety review on unblinded data • Full receptor binding of CAN10 to the target IL1RAP on immune cells • Strong biomarker data In addition to the clinical advances, three sc
Slide 4: I. Project Status
I. PROJECT STATUS
Slide 5: Current pipeline
Current pipeline Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 PDAC**, Nadunolimab TNBC*, NSCLC** Hidradenitis Suppurativa CAN10 Systemic Sclerosis New opportunities within IL1RAP CANxx platform PDAC – pancreatic cancer; TNBC – triple-negative breast cancer; NSCLC – non-small cell l
Slide 6: Cantargia in 2024/25
Cantargia in 2024/25 • Continuous generation of data in two clinical programs • Several clinical milestones during 2024 and 2025 • New data through publications and conference presentations INCREASED VISIBILITY AND UPCOMING CLINICAL DATA CRITICAL IN ATTRACTIVE/COMPETITIVE AREAS 6
Slide 7: CAN10
CAN10
Slide 8: CAN10 - Targeting IL-1 family in inflammation
CAN10 - Targeting IL-1 family in inflammation • Evidence of IL-1 family cytokines (IL-1, IL-33, IL-36) driving inflammatory diseases • These cytokines are commonly upregulated and operate together in several diseases • Blockade of individual IL-1 family members insufficient • IL-1 and IL-36 targeti
Slide 9: CAN10 first-in-human study ongoing
CAN10 first-in-human study ongoing • IV administration in healthy volunteers (SAD) • Ongoing, receptor occupancy documented • Strong PD effects • No safety signals • SC administration in subjects with mild to moderate plaque psoriasis (MAD) • Strong rational for IL1RAP blockade in psoriasis (blocks
Slide 10: CAN10 for treatment of Hidradenitis Suppurativa (HS)
CAN10 for treatment of Hidradenitis Suppurativa (HS) • CAN10 has strong potential to address an unmet medical need in HS • HS is a diverse disease with several inflammatory components involved in the pathology • IL-1a/, IL-33 and IL-36a//g are jointly upregulated in HS lesional skin, individual ta
Slide 11: Several manifestations of HS targeted by CAN10
Several manifestations of HS targeted by CAN10 • HS is a diverse disease with several inflammatory components involved in the pathology • IL-1α/β, IL-33 and IL-36α/β/γ are jointly upregulated in HS lesional skin, individual targeting is likely insufficient • Broad mode of action expected by IL1RAP b
Slide 12: Nadunolimab
NADUNOLIMAB
Slide 13: 1st line PDAC – Strong efficacy in patients with high tumor IL1RAP
1st line PDAC – Strong efficacy in patients with high tumor IL1RAP level OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50 50 iORR: 48% iORR: 30% Percent change from baseline 0 0 -50 -50 -100 -100 0 6 12 18 24 0 6 12 18 24 Months Months Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDA
Slide 14: Nadunolimab and alleviation of neuropathy
Nadunolimab and alleviation of neuropathy Phase 2 clinical data Mouse model 2.5mg/kg or higher levels of nadunolimab superior to Nadunolimab counteract chemotherapy induced neuropathy 1mg/kg Mechanical allodynia Grip strength (front) 4 150 ✱✱✱ ✱✱✱ ✱✱✱ ✱✱✱ *** *** *** *** *** *** *** *** *** *** 3 vi
Slide 15: TNBC – Promising early safety and efficacy (1st/2nd line)
TNBC – Promising early safety and efficacy (1st/2nd line) Nadunolimab combination with Gem/Carbo in 1st/2nd line metastatic Best responses according to RECIST OS and PFS TNBC: 100% Best change in tumor size 15 patients enrolled in the dose- 50% escalation phase: → Preliminary ORR: 60% 0% (1 CR, 8 PR
Slide 16: Nadunolimab mechanism of action
Nadunolimab mechanism of action Nadunolimab targets IL1RAP • Counteracts tumor promoting mechanisms in the tumor microenvironment • Alleviates neuropathy induced by chemotherapy IN ADDITION TO PROMISING EFFICACY NADUNOLIMAB COULD CONTRIBUTE TO SAFER COMBINATION THERAPIES 16
Slide 17: II. Finance
II. FINANCE
Slide 18: Financial highlights
Financial highlights MSEK Operating Expenses - Quarter Operating Expenses – First half-year 140 11 63 -39% 6 -30% 85 44 7 4 130 57 40 78 R&D Admin&Other 2023 Q2 2024 Q2 2023 2024 • Operating expenses decreased year over year by 30% to 44 (63) MSEK. • Operating expenses decreased year over year by 39
Slide 19: Available funds - quarterly development
Available funds - quarterly development MSEK 287 159 200 195 143 120 140 105 108 128 85 80 • Available funds decreased by 38 MSEK in the 55 quarter, from 143 to 105 (287) MSEK. 35 20 2023-06-30 2023-09-30 2023-12-31 2024-03-31 2024-06-30 Cash and bank balances Short-term investments 19
Slide 20: II. News flow and Q&A
II. NEWS FLOW AND Q&A
Slide 21: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC TNBC AML/MDS CAN10 milestones • Start Phase 2b trial in • Randomized Phase 2 •Start Phase 1/2 Q4 • Phase 1 data updates • NSCLC – Efficacy & 150-200 patients data H1 2025 2024 (DOD sponsored during 2024 and 25 biomarker data from with MDA) (including s